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Figure S1. TRIM9 upregulation in mouse brains after stroke. Related to Figure 1. (A) Expression profiles of the top20 5	  
upregulated genes in the indicated mouse organs based on the published RNAseq data which are currently available from 6	  
NCBI (see Methods). (B and C) Representative immunoblot (B) and quantification (C) of TRIM9 protein in ischemic brain 7	  
tissues from C57BL/6J mice at the indicated time-points after 30min MCAO. The antibody used here reacted with three 8	  
isoforms a/b/c of TRIM9 and the isoform b was used to quantify. n=3 mice per group. Data are shown as mean ± s.d. (D) 9	  
Immunoblots of TRIM9 protein in brain tissues from three 12-week-old C57BL/6J male or female mice without stroke. 10	  
 11	  
 12	  
 13	  
Figure S2. Characterization of Trim9-/- mice. Related to Figure 2. Immunostaining and quantification of neuronal and 14	  
glial markers on brain sections of Trim9+/+ and Trim9−/− mice: A and B for neuron (NeuN+) and neurofilament (SMI-312+); C 15	  
and D for oligodendrocytes (Olig2+) and oligodendrocyte precursor cell (OPC, Olig2+ and NG-2+ double positive); and E and 16	  
F for astrocytes (GFAP+) and microglia (Iba1+) in hippocampus. ns (non-significant) by Student’s t-test. Scale bar, 30µm. 17	  
n=5 mice per group. (G and H) The gross anatomy of the MCA territory of Trim9+/+ and Trim9−/− mice as shown by vascular 18	  
infusion of latex mixed with carbon black (see methods for details). The distance from the midline of the anastomotic line 19	  
between the MCA and anterior cerebral artery (ACA) vascular territory was determined from the frontal line. ns by Student’s 20	  
t-test. Scale bar, 2 mm. (I) Time course of CBF by laser doppler (LD) at 5 min intervals before, during and after 30 min of 21	  
MCAO in Trim9+/+ and Trim9−/− mice. ns by two-way ANOVA. n=3 mice per group. Data in B, D, F, H and I are shown as 22	  
the mean ± s.d. 23	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Figure S3. ELISA analysis of inflammatory mediators in ischemic mouse brains of Trim9+/+ and Trim9−/− mice. Related 29	  
to Figure 2. ELISA analysis of IL-6, TNF-α, IL-1β, and IL-10 in hemispheric brain tissues of Trim9+/+ and Trim9−/− mice 30	  
treated with 30 min MCAO and R24h (A) or R36h (B). n=5 mice per group. ***P<0.001 by one-way ANOVA followed by 31	  
Bonferroni’s post hoc analysis. ns, non-significant. Data are shown as mean ± s.d. 32	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Figure S4. NF-κB signaling activity in ischemic brains of Trim9+/+ and Trim9-/- mice. Related to Figure 4.  (A) 41	  
Immunoblot analysis of IκBα degradation in ipsilateral hemisphere of brain tissues from Trim9+/+ and Trim9−/− mice 24h after 42	  
30 min MCAO. n=3 mice upon MCAO. (B) Quantification of IκBα and p-p65 relative to actin after MCAO from A. *P<0.05 43	  
by Student’s t test. (C and D) Immunostaining (C) and quantification (D) of p-p65+NeuN+ cells in the peri-infarct regions of 44	  
ischemic brain fromTrim9+/+ and Trim9−/− mice at 24 h after 30min MCAO. Scale bar, 30µm. n=5 mice per group. 45	  
***P<0.001 by Student’s t-test. Data in B and D are shown as mean ± s.d. 46	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Figure S5. NF-κB signaling activity in Trim9+/+ and Trim9-/- neurons upon stimulation. Related to Figure 4.  (A) 51	  
Immunostaining of TRIM9 and MAP2 in the cultured primary cortical neurons of Trim9+/+ and Trim9−/− embryos. Scale bar, 52	  
30µm. (B-E) Immunoblot analysis (B and D) and quantification (C and E) of IκBα and p-p65 in Trim9+/+ and Trim9−/− 53	  
primary neurons upon TNF-α (25ng/ml) or IL-1β (25ng/ml) stimulation. *P<0.05 and ***P<0.001 by Student’s t-test. (F and 54	  
G) Representative immunoblot (F) and quantification (G) of IκBα and p-p65 in hNPC-derived neurons infected with 55	  
scramble- or TRIM9-specific shRNA lentivirus at 24h after 30 or 60min of OGD treatment. *P<0.05 and **P<0.01 by 56	  
Student’s t test. ns, non-significant. (H-K) Immunoblot analysis (H and J) and quantification (I and K) of IκBα and p-p65 in 57	  
Trim9−/− primary neurons infected with Vec, TRIM9 (WT) or TRIM9 SA mutant lentivirus, followed by TNF-α (25ng/ml) or 58	  
IL-1β (25ng/ml) stimulation. *P<0.05, **P<0.01 and ***P<0.001 by Student’s t-test. Data in C, E, G, I and K are shown as 59	  
mean ± s.d. 60	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Figure S6. AAV-PHP.B-mediated expression of TRIM9, not GFP and SA mutant, suppresses NF-κB signaling and 68	  
inflammatory cytokines production in ischemic mouse brains or primary neurons. Related to Figure 5. (A) 69	  
Representative immunoblots of GFP and Flag in Trim9−/− primary neurons and mouse embryo fibroblasts (MEFs) infected by 70	  
the indicated AAV. (B) Representative immunoblots of GFP, Flag-TRIM9 and actin in the brain tissues from Trim9−/− mice 71	  
injected with the indicated AAV. At 21d post-infection, brain tissue extracts were used for IB with indicated antibodies. (C 72	  
and D) Representative immunoblot (C) and quantification (D) of IκBα in tissue extracts from ischemic brain hemispheres of 73	  
Trim9−/− mice received indicated AAV vectors at 24h after 30min MCAO. n=5 mice per group. ***P<0.001 by Student’s t-74	  
test. ns, non-significant. (E and F) Representative immunoblot (E) and quantification (F) of IκBα level in Trim9−/− primary 75	  
neurons infected with indicated AAV vectors at 24h after 30min OGD treatment. ***P<0.001 by Student’s t-test. ns, non-76	  
significant. Data in D and F are shown as mean ± s.d. 77	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Table S1: The top 20 statistically upregulated genes from RNA-seq. Related to Figure 1. 86	  
Order Genes 
1 Hspa1b 
2 Hspa1a 
3 Atf3 
4 Lars2 
5 Mir6236 
6 Rplp2 
7 Nptx2 
8 Gadd45b 
9 Pabpc4 
10 Tmem252 
11 Rpl36 
12 Cebpb 
13 Rps10 
14 Rpl27a 
15 Trim9 
16 Odc1 
17 Rps21 
18 Hspb1 
19 Hsph1 
20 Stc2 	  87	   	  88	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Table S2: The genes from the pathway of neurological disease and inflammation in RNA-seq. Related 106	  
to Figure 1. 107	  
No. Genes No. Genes 
1 Ch25h 42 Pebp1 
2 Socs3 43 Gadd45b 
3 Myh9 44 Icam1 
4 Trim9 45 Zfp36 
5 Hspa1b 46 Bdbf 
6 Ddc 47 Gadd45g 
7 Flt3 48 Klf10 
8 Hspa1b/1a 49 Hmgn1 
9 Serpina3 50 Cebpd 
10 Mt2 51 Hmgb2 
11 Hba1/2 52 Myh11 
12 Ddb2 53 Tubb2b 
13 Hspa5 54 C11orf96 
14 Eef1g 55 Tgm2 
15 Grasp 56 Jun 
16 Tmsb4x 57 Ccl2 
17 Nptx2 58 Hexb 
18 Ttr 59 Dnajb1 
19 Adamts1 60 Ifrd1 
20 Pdyn 61 Ier5 
21 Egr4 62 Arc 
22 Etnppl 63 Mt-nd6 
23 Lmna 64 Rgs2 
24 Ier3 65 Relb 
25 Junb 66 Egr1 
26 Scn10a 67 Plaur 
27 Hmga1 68 Cebpb 
28 Maff 69 Sertad1 
29 Pdgfb 70 Hbb 
30 Inhba 71 Fos 
31 Hspa8 72 Ftl 
32 H3f3a/b 73 Sstr2 
33 Ccl4 74 Hs3st2 
34 Acta2 75 Lingo1 
35 Npas4 76 Tagln 
36 Pdlim1 77 Ptgs2 
37 Cd14 78 Wfs1 
38 Alas2 79 Ldha 
39 Cyr61 80 Hmgcr 
40 Hspb1 81 Ubc 
41 Apod   	  108	   	  109	   	  110	   	  111	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Table S3: Primers used in RT-qPCR. Related to Figure 2. 113	  
Gene  Forward primer (5’-3’) Reverse primer (5’-3’) 
Il-6 CAAAGCCAGAGTCCTTCAGAG GTCCTTAGCCACTCCTTCTG 
Il1β AAGGGCTGCTTCCAAACCTTTGAC ATACTGCCTGCCTGAAGCTCTTGT 
Tnfa CTTCTGTCTACTGAACTTCGGG TGATCTGAGTGTGAGGGTCTG 
Ccl11 CAGATGCACCCTGAAAGCCATA TGCTTTGTGGCATCCTGGAC 
Ccl3 CACCACTGCCCTTGCTGTT AGGAGAAGCAGCAGGCAGTC 
Ccl4 GCTCCAAGCCAGCTGTGGTA CGCTGGAGCTGCTCAGTTC 
Ccl5 TGCCCACGTCAAGGAGTATTT TCTCTGGGTTGGCACACACTT 
Cxcl10 TGCTGGGTCTGAGTGGGACT CCCTATGGCCCTCATTCTCAC 
Ccl2 CATCCACGTGTTGGCTCA GATCATCTTGCTGGTGAATGAGT 
Ccl9 CCCTCTCCTTCCTCATTCTTACA AGTCTTGAAAGCCCATGTGAAA 	  114	   	  115	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